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Abstract
The use of vascular endothelial growth factor (VEGF) inhibitors has
revolutionised the treatment of neovascular age-related macular degeneration
(nAMD) since the pivotal Phase III studies demonstrated their efficacy more
than 10 years ago. The Fight Retinal Blindness! project was developed to track
the treatment outcomes of patients with nAMD in real-world practice. Data
from this registry have been used to answer several clinically relevant questions
related to the treatment of nAMD including the effect of under-treatment, the
comparative effectiveness of different anti-vascular endothelial growth factor
agents, long-term treatment outcomes, identifying optimal treatment regimens
and the rate and outcomes of rare adverse events. Observational studies are a
valuable complement to the shortcomings of clinical trials and a combination of
data from real-world settings and clinical trials are necessary to provide evidence
on how to achieve the best outcomes for individual patients with nAMD.
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1 | INTRODUCTION
We are all fortunate that ways to treat neovascular age-
related macular degeneration (nAMD), which at least pre-
viously was one of the commonest causes of blindness,
have been discovered in our lifetimes. Rates of nAMD may
be reduced by public health campaigns directed at its
major environmental risk factor, cigarette smoking, but
these can only be partially effective since it is estimated
that the cause of the condition is 70% genetic.1,2 The Fight
Retinal Blindness! (FRB!) project was developed to track
different regimens used for vascular endothelial growth
factor (VEGF) inhibitors to identify which work best in dif-
ferent aspects of ‘real-world’ clinical practice.
2 | PHASE IV STUDIES AND REAL-
WORLD EVIDENCE
The post-marketing surveillance of interventions that
Phase IV studies provide forms a crucial piece of evidence
when evaluating treatments and interventions alongside
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‘efficacy’ data from Phase III clinical trials.3,4 Phase IV
studies serve three broad functions: (1) to monitor the
safety of new interventions in large populations, particu-
larly including specific groups not represented in clinical
trials, (2) to determine the ‘effectiveness’ of interventions
in routine clinical practice, and (3) to assess new ways to
use approved products for new indications.3 These obser-
vational, non-interventional studies rely on the use of
‘real-world evidence’ (RWE). RWE refers to the informa-
tion on health care from non-clinical trial settings such
as electronic health records (EHR), claims and billing
data, product and disease registries and data from per-
sonal devices and health applications.5 Such data from -
real-world settings have become increasingly important
with the transition of the healthcare system towards
evidence-based practice.
Randomised clinical trials (RCTs) remain the gold
standard for testing new interventions but have a number
of limitations, which RWE is better suited to address.
RCTs often have strict selection criteria so their results
cannot be generalised to the broader population seen in
practice, including children, pregnant women, the elderly
and those with co-morbidities.3,6 In contrast, RWE moni-
tors outcomes for all patients receiving treatment for a
condition, giving it greater external validity and relevance
for key stakeholders such as patients, clinicians, regula-
tors and reimbursement committees.7,8 Additionally, the
large sample sizes and lower cost of collecting real-world
data make it ideal for detecting rare adverse events and
assessing long-term safety and outcomes which would
not be feasible for a RCT.4,6,8 Many sources of real-world
data are obtained as part of standard procedures
(e.g., EHR and claims data) such that monitoring of
safety and treatment outcomes can continue long after
drugs have been approved for use. However, there are
many limitations of real-world data including lack of
standardised fields, lack of randomisation in compar-
ative analyses resulting in selection bias and generally
lower quality, more incomplete data. Importantly,
such data are not collected for the purpose of answer-
ing specific hypotheses or research questions.4,6 Spe-
cial care must therefore be taken when analysing and
interpreting RWE.
The importance of real-world data and limitations of
relying strictly on evidence from RCTs for the treatment
of nAMD are evident. Early clinical trials of VEGF inhibi-
tors for nAMD showed remarkable gains in vision rang-
ing from 6.5 to 10.7 letters after 2 years of treatment
every 4 weeks.9,10 However, these results could not be
replicated in routine clinical practice as the burden of
monthly anti-VEGF injections was not practical for most
patients, resulting in fewer injections and worse out-
comes.11-16 These real-world studies, which identified
previously unrecognised shortfalls in the delivery of anti-
VEGF treatment for nAMD, prompted a shift towards
individualised treatment regimens such as pro re nata
(PRN) and treat-and-extend (T&E) that could reduce the
treatment burden without sacrificing visual outcomes.17
3 | FRB! REGISTRY
The FRB! registry is the flagship module of the Save Sight
Registries (SSR; http://savesightregistries.org/) that spe-
cialises in tracking outcomes of retinal diseases with
audits for nAMD, choroidal neovascularisation (CNV)
other than nAMD, diabetic macular oedema and retinal
vein occlusion. The FRB! registry, established in 2009,
was designed as an online web-based tool to collect accu-
rate, standardised, high-quality data from routine clinical
practice, thereby distinguishing itself from other sources
of real-world data.18 Analyses of FRB! data have
addressed many clinically relevant issues in treating
nAMD in routine clinical practice, most of which will be
discussed in this review. Other modules in the SSR
include Fight Corneal Blindness!, Fight Glaucoma Blind-
ness and Fight Tumour Blindness!, which generally fol-
low the same structure.
Data are entered when treatment is started and then
at each clinical visit by the treating clinician or their
assistant. Treatment decisions, including choice of drug,
regimen and re-treatment criteria are at the discretion of
the clinician in consultation with the patient, with no
direction by the registry investigators, reflecting routine
clinical practice. The choice of data fields was determined
by a Steering Committee of retinal experts, and guided by
parsimony, validity and focus on tracking relevant out-
comes and emerging treatments in routine clinical prac-
tice. Also taken into consideration was the International
Consortium of Healthcare Outcomes Measures (ICHOM)
minimum set of standard outcome measures for macular
degeneration of which the FRB! registry is currently com-
pliant for nAMD.19 The full list of data fields recorded for
the nAMD audit is provided in Table 1.
A major concern of the utility of registries for research
is they are limited by the quality of the data which are
rarely validated.20 To address this, the FRB! registry has
quality assurance measures built into the system to ensure
that data are verified and are high-quality. Data can only
be ‘Saved’ if not all the mandatory data are available or
entered. The visit can only be ‘Finalised’ when all manda-
tory fields have been filled eliminating the possibility of
missing data. This validation process also confirms all
values are within predetermined ranges. Only finalised
data are available for analysis. Categorical data such as
angiographic lesion type are entered via a drop-down
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menu of pre-specified options instead of free text, which is
avoided throughout. Additionally, a data-quality review
was undertaken on a random subset of patients from clini-
cians who agreed to participate in the review.21 An inde-
pendent assessor was sent to the clinician's practices to
verify that the source data entered into the EHR matched
the data entered into the FRB! registry. There was an over-
all error rate of 3.5%, with visual acuity (VA) being the
most error-prone data field at 5.1% due to incorrect con-
versions from Snellen to logMAR. The FRB! registry has
since allowed clinicians to enter VA as Snellen with the
registry automatically converting it to logMAR to reduce
these errors. A possible concern was the high rate of mis-
sed visits (10.2%) that was identified. Such patients with
an unacceptably high rate of missed visits have generally
been excluded from FRB! analyses in the selection criteria
but ideally such data would be present.
As of 1 March 2021, the SSR contained data on more
than 40 000 eyes from 28 000 patients and has
700 clinicians participating spanning 23 countries across
Europe, Asia, Africa and the Pacific. This includes 29 290
eyes from 513 clinicians participating in the FRB!
registries.
4 | KEY FINDINGS FROM THE
FRB! REGISTRY
4.1 | Short- and long-term outcomes
from RWE
The FRB! investigators provided the first report of
12-month outcomes of intravitreal therapy for nAMD in
Australia using real-world data. These outcomes were
among the best in the world at the time, with a mean
gain of +4.7 letters after 12 months.22 In contrast, other
real-world studies reported either stabilisation (i.e., no
change from baseline),11,13 or much lower gains in vision
TABLE 1 List of data fields collected for the nAMD audit of the FRB! registry
Field Description Visit type Mandatory
Gender Gender of patient Baseline only Yesa
Year of birth Patient year of birth Baseline only Yes
Ethnicity Ethnicity of patient Baseline only Noa
Smoking status Smoker, ex-smoker or non-smoker Baseline only Noa
Postcode Postcode of patient Baseline only No
Angiographic lesion type Lesion classification using fluorescein angiography and/or
optical coherence tomography, judged by treating clinician
Baseline only Yesa
Previous treatment Pre-treatment status of the patient Baseline only Yes
Ocular conditions Other relevant ocular conditions that may affect vision such as
glaucoma or cataract
Baseline only Yes
Date of visit Date of patient visit Baseline and follow-up Yes
Treatment Treatment administered for that visit if any Baseline and follow-up Yes
Visual acuity Number of letters read on a logMAR scale. Best of uncorrected,
corrected or pinhole. May be entered in Snellen
Baseline and follow-up Yes
Intraocular pressure Intraocular pressure in mmHg Baseline and follow-up No
CNV activity Lesion activity status graded as inactive, active with subretinal
fluid only, or active with any combination of fluid excluding
subretinal fluid only
Baseline and follow-up Yes
Macular atrophy Presence/absence and location of macular atrophy Baseline and follow-up Yes
Subretinal fibrosis Presence/absence and location of subretinal fibrosis Baseline and follow-up
Adverse events Treatment complications Follow-up only Yes
Ocular events Other procedures given not directly related to treatment for
nAMD such as cataract extraction or vitrectomy
Follow-up only Yes
Discontinuation Reason for discontinuation of patient from database, including
non-treatment related reasons such as death
Follow-up only No
Abbreviations: CNV, choroidal neovascularisation; FRB!, Fight Retinal Blindness!; nAMD, neovascular age-related macular degeneration.
aOption to select undisclosed or unknown even if mandatory.
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at 12 months.12,14,16 The superior outcomes found in
Australia were almost certainly due to the higher mean
of 7 injections compared with the 3–5 injections adminis-
tered elsewhere. A follow-up FRB! analysis used a ‘mat-
ched’ cohort with the same inclusion criteria as the
landmark Minimally Classic/Occult Trial of Anti-VEGF
Antibody Ranibizumab (MARINA) clinical trial, and
reported a mean gain of +5.5 letters.9,23 Although these
real-world results were still lower than the RCTs, they
were nonetheless reassuring and indicated VEGF inhibi-
tors could achieve good achieve good outcomes in routine
clinical practice without the need for monthly injections.
Reports of long-term outcomes of treatment are still
limited even as many patients have been treated with
VEGF inhibitors for over 10 years, which is much longer
than the 2-year outcomes reported by the pivotal
MARINA and Anti-VEGF Antibody for the Treatment of
Predominantly Classic Choroidal Neovascularization in
Age-Related Macular Degeneration (ANCHOR) clinical
trials in 2006.9,24 An FRB! analysis in 2015 evaluated
long-term outcomes of nAMD in 1212 eyes, with 549 com-
pleting 5 years of follow-up, representing the largest pub-
lished set of long-term data available at the time.25 Good
outcomes were reported, with vision remaining stable for
approximately 5 years although more than half of
patients were lost to follow-up. The Seven-Year Observa-
tional Update of Macular Degeneration Patients Post-
MARINA/ANCHOR and HORIZON Trials (SEVEN-UP)
study, which provided the only other long-term data
available at the time, reported a mean vision loss of 8.6
letters at 7 years with only half as many injections as the
FRB! cohort.26 The Comparison of Age-related Macular
Degeneration Treatment Trials (CATT) published later
reported vision loss at 5 years, again with fewer injec-
tions.27 Other factors that may have contributed to the
better outcomes in the FRB! registry include differences
in baseline vision, demographics and the treatment regi-
men with a treat and extend regimen likely to have been
used by the FRB! practitioners and PRN approach by the
other studies.28
The first 10-year outcomes data on VEGF inhibitors
for nAMD were published using data from the FRB! reg-
istry in 2020.29 Eyes completing 10 years of continuous
treatment in Australia and New Zealand had reasonably
good outcomes with a mean loss of just 0.9 letters, in con-
trast to the Swiss cohort who lost a mean of 14.9 letters.
The higher median number of injections in the Australia
and New Zealand cohort (53 vs. 42 over 10 years) likely
explained most of the difference between regions. This
was despite a transition towards more intensive
treatment in the Swiss cohort in later years, likely when
evidence of poorer real-world outcomes from under-
treatment became widespread. Subretinal fibrosis and
macular atrophy were the most common causes of long-
term vision loss but, importantly, they did not develop
universally in eyes receiving treatment for 10 or more
years. A separate analysis of 10-year outcomes in France,
also using FRB! registry data, had comparatively worse
outcomes with a loss of 18 letters after a median of only
27.5 injections over 10 years.30 A number of 10-year
follow-up studies have since been published, confirming
the relationship between injection frequency and that
vision can be maintained at 10 years with ongoing
treatment.31,32
Overall, the FRB! registry presented an optimistic
prognosis of real-world outcomes compared with other
early observational studies, both short- and long-term.
Australian patients may do well because the drugs are
reimbursed without restriction and there enough practi-
tioners who are adequately reimbursed to do the neces-
sary number of injections. Beyond the need for more
frequent treatment, further analyses into the possible
causes and predictive factors of poor outcomes, including
macular atrophy and subretinal fibrosis, may improve
further the long-term outcomes of patients with nAMD.
4.2 | Variable dosing regimens
The variable T&E regimen attempts to balance
maximising visual outcomes while reducing treatment
frequency, by gradually extending the intervals between
treatments while keeping the CNV lesion inactive and
reducing the interval when it is active.33 It presumes that
the lesion will always reactivate, and it aims to give the
next treatment just before that event. Unlike PRN,
another variable regimen, T&E does not require monthly
monitoring visits thus reducing the burden of visits
although both generally begin with monthly dosing until
the lesion becomes inactive. The FRB! investigators
analysed the outcomes of T&E using ranibizumab and
reported a mean vision gain of +5.3 letters at 2 years with
a mean of 13 injections over 14.8 visits, effectively reduc-
ing the treatment frequency by nearly half that of a
monthly regimen without monitoring visits while still
achieving good outcomes.34 A subsequent FRB! analysis
of T&E using aflibercept similarly found good outcomes,
a mean gain of +6 letters after 2 years with a mean of
13.6 injections.35 Further evidence, including a meta-
analysis and systematic review, indicated that T&E
achieved better outcomes than PRN.15,17,36,37
The T&E regimen consists of an induction phase,
with monthly treatment intervals until the CNV lesion
becomes inactive, followed by the maintenance phase in
which treatment intervals are extended as long as the
CNV lesion is inactive. Despite overwhelming evidence
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of the efficacy of T&E, there were still many uncertainties
and variations in management decisions, particularly
during the maintenance phase. The FRB! registry gave a
detailed description of patterns and outcomes during
both phases of T&E to provide clinicians with further
guidance.38,39 The median duration of the induction
phase was reported to be 15 weeks, with 61% of CNV
lesions becoming inactive with just 1–3 injections.38
Interestingly, lesions induced with treatments at intervals
exceeding 5 weeks required disproportionately more time
and injections to become inactive, emphasising the
importance of maintaining monthly treatment intervals
early on. During the maintenance phase, treatment inter-
vals were gradually extended before stabilising after
12 months, with most lesions settling at approximately
8-weekly intervals.39 Of note, there was a substantial risk
of lesion re-activation when treatment intervals exceeded
12 weeks suggesting that 3 monthly is a reasonable cap
for extending intervals.
Variants of the T&E regimen continued to evolve in
routine clinical practice amidst the difficulty of
maintaining long-term treatment adherence and con-
cerns regarding the risk of developing macular atrophy.
Reports of a ‘treat-extend-stop’ variant were published,
raising the possibility that some patients may be able to
stop treatment altogether.40,41 An FRB! analysis investi-
gated the outcomes of eyes in which treatment suspen-
sion, defined as ≥3 months of documented lesion
inactivity with no treatment unless the lesion re-acti-
vated, was attempted.42 Approximately 41% of eyes that
suspended treatment re-activated within the first year,
increasing to 79% by the fifth year. Risks of re-activation
were reduced in patients with poor vision or if they had
been treated for at least 3 years prior to suspension.
Vision that was lost due to re-activation was not recov-
ered despite resuming treatment. Thus the decision to
suspend treatment must be balanced against the possibil-
ity of irreversible vision loss which for some clinicians
may be too risky.43
4.3 | Comparative efficacy of
ranibizumab and aflibercept
Bi-monthly aflibercept was found to be equivalent to
monthly ranibizumab in the Phase III clinical trial,
suggesting that it might have a longer duration of
action.44 The FRB! investigators directly compared VA
and injection frequency outcomes between ranibizumab
and aflibercept in routine clinical practice.45 Visual out-
comes at 12 months did not differ significantly between
the two drugs (adjusted mean [95% CI] VA change +4.9
[1.5, 8.3] letters for aflibercept vs. +3.0 [0.2, 6.3] letters
for ranibizumab; p = 0.26). There was also no evidence
that aflibercept was injected less frequently than
ranibizumab in real-world practice (mean 8.0 injections
aflibercept for vs. 8.1 for ranibizumab), possibly due to
the predominant use of T&E since the treatment intervals
were extended regardless of drug choice. These findings
have since been replicated in a RCT and observational
studies.46,47 A follow-up comparison by the FRB! investi-
gators extended the analysis to 36 months and again
found no difference in visual outcomes or treatment fre-
quency between ranibizumab and aflibercept.48 Thus far,
the FRB! registry has produced the longest and only
36-month comparison between these two drugs in real-
world practice.
As the treatment effect of anti-VEGF injections for
nAMD tends to be most pronounced after the first
injection,24,49 a 4-week analysis was reasoned to offer the
purest indication of the relative efficacy of each drug with
fewer confounders such as treatment regimen and patient
dropout.50 A sub-analysis of 4 week results in the Com-
parison of Ranibizumab and Aflibercept for the Develop-
ment of Geographic Atrophy in (Wet) AMD Patients
(RIVAL) clinical trial reported more eyes receiving
aflibercept lost vision 4 weeks after the first injection.47
This result was not confirmed by the FRB! analysis, with
an adjusted mean (95% CI) VA change of +3.5 (2.6, 4.4)
letters for aflibercept and +3.6 (2.9, 4.3) letters for
ranibizumab 4 weeks after the first injection in
treatment-naïve eyes.50 It appears that change in VA after
the first injection for nAMD is more likely to be driven
more by baseline characteristics, such as age, baseline
VA and lesion characteristics, than by the drug.
4.4 | Fluid management
Treatment decisions under the PRN or T&E regimens are
largely determined by the activity of the CNV lesion,
indicated mainly by the presence of subretinal fluid
(SRFL) or intraretinal fluid (IRFL), with the goal of keep-
ing the lesion inactive with the fewest injections.17,33
Eyes with chronically active lesions generally receive
monthly treatment under the guidelines of PRN or T&E.
However, few data are available on the outcomes of per-
sistent lesion activity to assess whether monthly injec-
tions are necessary in these eyes. Interestingly, an FRB!
analysis investigating the 12-month outcomes found that
persistently active eyes (CNV lesion graded as active at
every visit) achieved a similar mean VA gain (+5.5 let-
ters) with a similar mean number of injections (8.3) to
those with less active lesions (+6.2 to +8.3 letters, 7.7 to
8.5 injections for the three remaining quartiles of lesion
activity).51 Although these data hinted at the possibility
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that fluid could be tolerated to an extent, the long-term
effects of chronic lesion activity were still unknown.
There has since been some evidence that a degree of
fluid may be tolerated, particularly SRFL which could
protect against the development of macular atrophy.52-55
The development of macular atrophy and its possible link
to treatment with VEGF inhibitors has been a growing
concern given it is one of the main causes of irreversible
long-term vision loss.25,29,55,56 An FRB! analysis reported
the 5-year prevalence of macular atrophy at 42% and 48%
at 9 years, with the strongest risk factor for atrophy being
the proportion of visits in which the lesion was graded
inactive (adjusted odds ratio 3.72 for the highest
vs. lowest quartile of inactive gradings).57 These results
support the hypothesis that fluid may protect against the
development of atrophy in the long-term, contradicting
the goals of PRN and T&E to keep the CNV lesion inac-
tive. The prevalence of macular atrophy also increased
with the number of anti-VEGF injections, but whether
the injections were the direct cause of atrophy or
whether it was simply the natural history of AMD could
not be determined.
The other major cause of long-term vision loss is sub-
retinal fibrosis which is also untreatable and irrevers-
ible.27,29 In contrast to macular atrophy, the presence of
fluid has been identified as a potential risk factor for the
development of subretinal fibrosis.58,59 This idea was
again supported by FRB! data, with a higher proportion
of visits with active CNV associated with a greater risk of
developing subretinal fibrosis (adjusted odds ratio 1.58
for the highest vs. lowest tertile of activity).60 The preva-
lence of subretinal fibrosis was reported to be approxi-
mately 50% after 10 years of treatment, similar to the
prevalence of macular atrophy.
This presents a dilemma for clinicians who wish to
preserve long-term vision, since too little fluid may
increase the risk of macular atrophy whereas too much
fluid may increase the risk of subretinal fibrosis. The
optimal approach appears to be to tolerate some retinal
fluid, allowing for an intermediate level of fluid for the
best long-term outcomes. An FRB! analysis of the 5-year
outcomes by lesion activity, a follow-up of the analysis of
12-month outcomes of persistently active lesions, sought
to investigate this hypothesis (unpublished data). This
analysis indeed found that eyes in the highest tertile of
disease activity (most active) had the worst outcomes at
5 years, with an adjusted mean (95% CI) VA change of
2.5 (4.2, 1.3) letters, followed by the lowest tertile
(least active, 0.5 [1.8, 1.1] letters), with the middle ter-
tile (moderately active) achieving the best outcomes
(+1.8 [0.2, 3.4] letters). Additionally, the percentage of
eyes with macular atrophy decreased with activity (56%,
47% and 26% in the low, moderate and high tertiles of
activity respectively) while subretinal fibrosis increased
with activity (27%, 36% and 42%).
These data present a compelling narrative regarding
the importance of appropriate fluid management to pre-
serve long-term vision. However, a major limitation in
the two analyses just described was the lack of distinction
between SRFL and intraretinal fluid (IRFL). Increasingly,
it appears the location of the fluid is important in the
decision to treat or tolerate fluid.52 While there is evi-
dence that SRFL may be protective against atrophy and
tolerated to an extent,52,55 IRFL has been reported to be
associated with poorer visual outcomes and an increased
risk of MA.55,61,62 Since 2017 onwards, clinicians in the
FRB! registry were required to grade active lesions being
either ‘active SRFL only’ or ‘active with any combination
of fluid excluding SRFL only’. A 12-month FRB! analysis
utilising these new gradings grouped eyes based on
whether they were mostly inactive, mostly active with
SRFL only or mostly active with non-SRFL only
(i.e., IRFL).63 It found that eyes that were mostly active
with SRFL only achieved similar mean (95% CI) adjusted
VA gain (+7.5 [5.6, 9.4] letters) to those that were mostly
inactive (+7.6 [5.7, 9.6] letters) while those that were
mostly active with non-SRFL only gained the least (+3.6
[1.9, 5.3] letters). This analysis confirmed the results of
the 24-month FLUID RCT which also reported good out-
comes when SRFL was tolerated.52 Longer-term data will
be needed to determine in more detail the relationship
between IRFL, SRFL and the development of macular
atrophy and subretinal fibrosis. Regardless, optimal appli-
cation of PRN and T&E in the long-term will likely
involve tolerating some degree of fluid, most likely SRFL.
4.5 | Poor outcomes and adverse events
Despite the effectiveness of anti-VEGF for most eyes with
nAMD, some respond poorly to treatment with major
clinical trials reporting a loss of ≥15 letters in approxi-
mately 4%–6% of eyes at 12 months and 8%–10% at
24 months.9,10 Poor long-term outcomes are commonly
due to macular atrophy or subretinal fibrosis but this
does not account for all causes of long-term vision
loss.25,29 An FRB! analysis detailing the incidence, char-
acteristics and factors that contribute to vision loss over
5 years reported an estimated 23% of eyes had a sustained
loss of ≥15 letters at 5 years (loss without recovery by the
endpoint), with 11% losing ≥30 letters.64 Older age, fewer
injections (under-treatment) and eyes with the highest
proportion of visits with active CNV were associated with
sustained vision loss. Another FRB! analysis that sepa-
rately analysed smoking status as a potential risk factor
for poor outcomes found it was associated with a lower
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adjusted mean (95% CI) VA change at 12 months (+4.6
[1.5, 7.8] letters) compared with ex-smokers (+5.9 [3.4,
8.3] letters) and non-smokers (+8.0 [6.0, 10.0] letters).65
Although macular atrophy and subretinal fibrosis are
the most common causes of poor long-term outcomes for
nAMD patients, adverse ocular events specifically associ-
ated with anti-VEGF therapy are quite rare.8,66 The rarity
of these events makes real-world data more suited to
monitoring their rate and subsequent than RCTs. One of
the more severe complications of anti-VEGF treatment is
endophthalmitis, which may be infectious or non-infec-
tious. Data from the FRB! registry estimated the inci-
dence of endophthalmitis was low and did not increase
with each successive injection, with a per injection risk of
infectious endophthalmitis at 0.020% and 0.012% for non-
infectious endophthalmitis.67 These closely approximated
the results from a meta-analysis of real-world outcomes
which estimated the rate at 0.026%.15 However, the FRB!
data also suggested non-infectious endophthalmitis was
more common with the unlicenced anti-VEGF agent,
bevacizumab (0.081%), compared with ranibizumab
(0.005%) and aflibercept (no cases recorded). Approxi-
mately three quarters of infectious and two thirds of non-
infectious endophthalmitis cases recovered vision to
within 10 letters of their pre-endophthalmitis VA after
having lost approximately a mean of 20 letters of vision.
These outcomes were slightly better than previous
reports68 and may have been because treatment intensity
was maintained. Continuing anti-VEGF treatment after
an attack of endophthalmitis has resolved therefore
seems to be of some benefit.
Treatment with anti-VEGF may also increase the risk
of retinal pigment epithelium (RPE) tears.69,70 Although
continued treatment with anti-VEGF after the RPE tear
showed beneficial outcomes,69 reports of long-term out-
comes have been less encouraging despite persistent
treatment.71 An FRB! analysis focusing on the visual out-
comes of RPE tears identified two distinct responses
based on when the tear occurred and the response to
treatment prior to the tear.72 Eyes which had an early
tear occurring before 6 months (approximately 70% of the
tears recorded) had experienced a very strong improve-
ment in vision prior to the tear. This positive response
may be associated with a greater tendency for the CNV to
shrink, which causes the tear.70 Vision loss due to these
‘early’ tears recovered quite well, reaching levels compa-
rable to matched controls that did not develop a tear.
When tears occurred late, after 6 months of treatment,
the neovascular complex is less likely to shrink.73 VA in
these eyes with ‘late’ tears was in decline even prior to
the tear so it is possible that the tear was due to progres-
sive growth of the CNV and the consequent atrophic
damage to the RPE in eyes that were already not
responding well to treatment. The long-term prognosis of
eyes affected by RPE tears may therefore be related more
to the patient's response to therapy rather than to the tear
itself.
4.6 | Angiographic lesion subtypes
The Macular Photocoagulation Study in 1991
characterised lesion subtypes based on fluorescein angi-
ography as ‘classic’, or well-defined CNV, and ‘occult’,
or poorly defined, CNV.74 This classification scheme was
considered clinically important since the natural history
and response to treatments available at the time, particu-
larly photodynamic therapy (PDT) with verteporfin, var-
ied between the CNV types.75 An updated classification
scheme using fluorescein angiography and ocular coher-
ence tomography was proposed which identified Type
1 lesions (generally occult), Type 2 lesions (generally clas-
sic) and Type 3 which corresponded to retinal angioma-
tous proliferation (RAP).76 While the Macular
Photocoagulation Study classification scheme was subse-
quently used when selecting and monitoring eligible
patients for RCTs for anti-VEGF,9,24 its clinical relevance
once anti-VEGF became the first-line treatment had not
been questioned. A 5-year FRB! analysis compared Type
1 and Type 2 lesions to assess whether there were differ-
ences in real-world visual outcomes or treatment inten-
sity when treated with anti-VEGF injections. Mean
baseline vision was higher in occult CNVs (56.9 letters)
than the minimally (52.9 letters) and predominantly clas-
sic (49.1 letters) variants and was still higher at 5 years.
However, lesion type did not affect 5-year VA improve-
ments after multivariate adjustment for age, lesion size
and baseline vision. There was also no difference in injec-
tion frequencies with Type 1 and Type 2 lesions receiving
29–30 injections over 5 years. Thus, the classification of
CNV lesions into Type 1 and Type 2 may be irrelevant to
clinicians and patient management when eyes are treated
with intravitreal therapy.
RAP lesions were thought to have a poorer response
to treatment and worse functional outcomes than Type
1 and Type 2 lesions when they were first described.77 A
sub-analysis of RAP lesions in the CATT clinical trial,
however, reported similar outcomes at 2 years compared
with other lesion types.78 The lack of large studies or
real-world data comparing RAPs with non-RAP lesions
may have prolonged the perception that RAPs were more
difficult to treat. An FRB! analysis compared the
24-month outcomes of RAPs with a control cohort of
other lesion types matched on baseline vision, year
of treatment initiation and anti-VEGF agent used. RAP
lesions actually had better mean (95% CI) visual
658 NGUYEN ET AL.
outcomes at 24 months (+5.1 [2.8, 7.3] letters) than the
matched controls (+2.5 [1.0, 4.0] letters).79 The signifi-
cantly smaller lesion size characteristic of RAP lesions,
along with the lower levels of lesion activity observed
may have contributed to these better outcomes. These
data confirm the results from the CATT sub-analysis and
adds to the body of evidence that anti-VEGF is just as
efficacious for RAP lesions as it is for other forms of sub-
retinal neovascularisation.
A unique variant of Type 1 choroidal neovascularisation
is polypoidal choroidal neovascularisation (PCV), which is
more commonly found among Asian populations than Cau-
casian populations.80 Unlike other lesion subtypes, there is
some evidence that the addition of PDT in combination
with anti-VEGF achieves better outcomes than anti-VEGF
monotherapy, however more data are required to confirm
these results and data from routine clinical practice are lac-
king.81,82 Investigators from the FRB! registry identified
patients with PCV lesions treated with either anti-VEGF
monotherapy or combination anti-VEGF with PDT.83 Eyes
that received combination therapy in routine clinical prac-
tice presented with significantly lower baseline vision, possi-
bly because PDT was only considered in more advanced
cases or patients in Asia, where PDT is more commonly
used, seek treatment later. However, mean (95% CI) visual
outcomes at 12 months after multivariate adjustment were
significantly better following combination therapy (+16.9
[10.6, 23.3] letters) than with anti-VEGF monotherapy
(+8.2 [5.2, 11.3] letters). While previous RCTs comparing
combination with anti-VEGF monotherapy used
ranibizumab, PCV patients from the FRB! registry were
mostly receiving unlicenced bevacizumab which was the
predominant drug available in Singapore and New Zealand.
Regardless, the FRB! study provides additional evidence for
the use of combination anti-VEGF with PDF for patients
diagnosed with PCV.
4.7 | International outcomes and audits
The international expansion of the FRB! registry has
allowed participating counties to conduct audits into
their own outcomes from routine clinical practice to
benchmark outcomes, identify potential areas for
improvement and highlight certain idiosyncrasies. Inves-
tigators from Spain were interested in comparing out-
comes between study sites within the same hospital but
utilising different treatment strategies, fixed bi-monthly
with aflibercept and T&E.84 No significant differences in
visual outcomes were found but the individualised T&E
approach was able to reduce the burden of treatment for
many eyes. An analysis from France reported a modest
mean (95% CI) gain in visual outcomes of +3.3 (0.7, 5.9)
letters at 12 months, comparatively lower than RCTs and
previous FRB! reports, possibly due to the use of the PRN
regimen.85 Practitioners from the Netherlands, where
bevacizumab is the first-line treatment according to the
guidelines of the Dutch Ophthalmological Society,
benchmarked their outcomes against a control cohort
from Australia and Switzerland where ranibizumab or
aflibercept were used.86 They reported similar visual out-
comes at 12, 24 and 36 months, albeit at the cost of signif-
icantly more injections, visits and switching to alternative
VEGF inhibitors. Investigators from Singapore analysed
the effects of delayed re-treatment of active disease in a
large tertiary centre in Singapore, distinct from under-
treatment traditionally defined as a low number of
injections which does not necessarily consider disease
activity.87 They found that patients with delayed treat-
ment of active disease had worse outcomes even when
the absolute number of injections were similar, highlight-
ing the importance of timely re-treatment of active
disease with the possible exception of SRFL.
5 | FUTURE RESEARCH
FRB! investigators are committed to tracking the out-
comes of new drugs as they are released for use in real-
world practice. These drugs, such as brolucizumab and
faricimab, achieved visual improvements for nAMD that
were non-inferior to currently approved agents in the piv-
otal Phase III studies with more eyes able to be treated at
3 and 4 monthly intervals.88,89 Whether they also achieve
this in real-world practice, where we anticipate that they
will be administered according to a treat and extend regi-
men, will only be established by observational registries
such as FRB!
The FRB! project has plans to offer its free software
more widely, in keeping with its philosophy that tracking
outcomes will drive better outcomes across the board.
There are plans to make gains in Asia over the next
5 years similar to those that have been made in Europe
over the last 5 years. A new module has recently been
released to track the outcomes of people with uveitis
while standard outcome sets for both inherited retinal
diseases and retinopathy of prematurity have been
identified.
One challenge for observational studies of retinal
disease is to link automatically clinical outcome sets
with images of the retina, such as ocular coherence
tomography scans, which are an indispensable part of
real-world care. This will facilitate studies that corre-
late function and outcomes with anatomical outcomes
which lend themselves to analysis by artificial
intelligence.
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6 | CONCLUSIONS
RCTs only get us halfway there. If we want to get the best
outcomes for our patients from new treatments, we also
need to see the data from real world practice. This has been
particularly the case for conditions such as nAMD, for
which the pivotal clinical trials tend to use treatment regi-
mens that practitioners and patients in real-world practice
would mostly be unable to follow even if they wanted
to. Observational studies are also essential to track out-
comes over the lifetime of a patient, which clinical trials
cannot do. The FRB! project has, along with other observa-
tional studies, helped to establish treatment regimens for
routine clinical practice which are feasible and effective.
Observational registries will continue to provide essential
evidence for practice as the first generation of VEGF inhibi-
tors come off patent and second generation agents, together
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